Murlentamab, a Low Fucosylated Anti-Müllerian Hormone Type II Receptor (AMHRII) Antibody, Exhibits Anti-Tumor Activity through Tumor-Associated Macrophage Reprogrammation and T Cell Activation.

Cancers (Basel) · 2021 · PMC8070390 · PMID 33924378

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

combo at D24: p = 0.101 as determined with the Mann–Whitney one tail test), we showed a trend towards a potentiated effect with the murlentamab/pembrolizumab combo-therapy ( Figure 5 E).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.